Yahoo Finance Microbix Biosystems First Quarter 2024 Earnings: EPS: CA$0.018 (vs CA$0.009 loss in 1Q 2023)
Microbix Biosystems (TSE:MBX) First Quarter 2024 Results
Key Financial Results
Revenue: CA$8.41m (up 236% from 1Q 2023).
Net income: CA$2.46m (up from CA$1.30m loss in 1Q 2023).
Profit margin: 29% (up from net loss in 1Q 2023).
EPS: CA$0.018 (up from CA$0.009 loss in 1Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Microbix Biosystems Earnings Insights
Looking ahead, revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 59% growth forecast for the Biotechs industry in Canada.
Performance of the Canadian Biotechs industry.
The company's shares are up 3.8% from a week ago.
Risk Analysis
We should say that we've discovered 2 warning signs for Microbix Biosystems (1 makes us a bit uncomfortable!) that you should be aware of before investing here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
